gb001
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2021 (NCT05125211)
Timeline
Indications
Studied for
Mechanism of action
- Prostanoid DP receptorINHIBITOR
PTGDR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06429566 | Phase 2 | Jul 18, 2023 | Government of China |
| NCT05125211 | Phase 1 | Nov 20, 2021 | Government of China, Nanjing Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2021 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1